
Opinion|Videos|August 23, 2024
Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy
Acute lymphoblastic leukemia specialists explore resources and strategies to address the logistical hurdles of CAR-T therapy implementation, while also examining patient support programs designed to enhance treatment accessibility and adherence.
Advertisement
Video content above is prompted by the following:
- What are some resources and/or strategies to help support and solve these logistical challenges?
- Please comment on different CAR-T patient support programs (lodging, support resources etc.)
- At your institution, are patients who are eligible for CAR-T cell Therapy discussed at a multidisciplinary meeting to discuss these challenges?
- Are Apheresis or cell laboratory members, social workers, case managers, nurses, pharmacy involved? If so, what are each discipline roles?
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5


